Article Text

Download PDFPDF

Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis
  1. Hai Zeng1,
  2. Meng Luo2,
  3. Zunjiang Li2,
  4. Junru Wen3,4,
  5. Guoxin He5,
  6. Yuelin Jin4,
  7. Wenbin Fu6,7,
  8. Peng Zhou8
  1. 1 Department of Acupuncture and Moxibustion, The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
  2. 2 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
  3. 3 Shanghai University of Traditional Chinese Medicine, Shanghai, China
  4. 4 Shanghai University of Medicine & Health Sciences, Shanghai, China
  5. 5 The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
  6. 6 Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
  7. 7 Shenzhen Bao’an Research Center for Acupuncture and Moxibustion, Shenzhen, China
  8. 8 Department of Acupuncture and Moxibustion, Shenzhen Bao’an Traditional Chinese Medicine Hospital Group, Shenzhen, China
  1. Correspondence to Professor Wenbin Fu; zjkzh{at}139.com and Professor Peng Zhou; hdnjswls{at}163.com

Abstract

Introduction High body mass index (BMI) is associated with risk of diabetes. Lorcaserin is a selective 5-hydroxytryptamine 2C agonist which exerts robust benefits on long-term weight loss by suppressing appetite among adults with overweight or obesity. The magnitude of efficacy of lorcaserin for preventing and remitting type 2 diabetes mellitus (T2DM) among those people remains undefined. Therefore, we plan to conduct this systematic review and meta-analysis to aggregate data from all published studies with regard to the issue to acquire reliable evidence.

Methods and analysis We will search various databases for relevant trials published up to June 2019. Randomised controlled trials investigating the efficacy of lorcaserin for preventing and remitting T2DM among overweight and obese population will be included. A standardised data form will be used to complete data search and extraction in duplicate. All discrepancies will be resolved by consensus. The primary outcome will be incidence of T2DM in patients with pre-diabetes. Secondary outcomes will include achievement of normoglycaemia in people with pre-diabetes, remission of hyperglycaemia in patients with diabetes, the proportion of patients with weight loss of at least 5% or 10% and hypoglycaemia incident. Data synthesis and statistical analysis will be performed for each outcome with Stata V.14.0.

Ethics and dissemination Ethics approval is not required. Results of our study will be submitted to a peer-review journal.

PROSPERO registration number CRD42019119136.

  • diabetes
  • lorcaserin
  • meta-analysis
  • obesity
  • prediabetes

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • HZ, ML and ZL contributed equally.

  • Contributors WF and YJ were the guarantors. HZ, ML and JW contributed to study design. JW, ML and ZL drafted the protocol. GH and ML registered the protocol and designed the search strategy. HZ, WF, YJ and PZ revised the protocol. All authors reviewed and approved the final manuscript.

  • Funding This research was supported by the Sanming Project of Medicine in Shenzhen (No. SZSM201806077) and Shenzhen Bao’an Traditional Chinese Medicine Hospital Group.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.